A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours

European Journal of Cancer

Volumn 44, Issue 12, 2008, Pages 1684-1692

  Undevia, Samir D ^a   Innocenti, Federico ^a   Ramirez, Jacqueline ^a   House, Larry ^a   Desai, Apurva A ^a   Skoog, Linda A ^a   Singh, Deepti A ^a   Karrison, Theodore ^a   Kindler, Hedy L ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Pharmacokinetics; Phase I; Quinoxaline; R(+)XK469; XK469

Indexed keywords

2 [4 [(7 CHLORO 2 QUINOXALINYL)OXY]PHENOXY]PROPANOIC ACID; QUINOXALINE DERIVATIVE; XK 469;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; ENANTIOMER; FATIGUE; FEMALE; FEVER; GENETIC POLYMORPHISM; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUINOXALINES; TREATMENT OUTCOME;

EID: 48249135416     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.05.018     Document Type: Article

References (22)

1. LoRusso P.M., Parchment R., Demchik L., et al. Preclinical antitumor activity of XK469 (NSC 656889). Invest New Drugs 16 (1999) 287-296
2. Wiegand RA, Doyle TD, Grieshaber CK et al. Normal-phase separation of XK469 enantiomers (R:NSC-698215, S:NSC-698216) applied to preclinical pharmacology. In: Proceedings of the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics; 1999. Washington, DC [Abstract 542].
3. Zheng H., Covey J.M., Tosca P.J., Turner N., and Chan K.K. Chiral high-performance liquid chromatographic analysis of the enantiomers of XK469, a new antitumor agent, in plasma and urine. J Pharm Biomed Anal 28 (2002) 287-294
4. Zheng H., Jiang C., Chiu M.H., Covey J.M., and Chan K.K. Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIβ poison in the rat. Drug Metab Dispos 30 (2002) 344-348
5. Gao H., Huang K.C., Yamasaki E.F., Chan K.K., Chohan L., and Snapka R.M. XK469, a selective topoisomerase IIβ poison. Proc Natl Acad Sci USA 96 (1999) 12168-12173
6. Snapka R.M., Gao H., Grabowski D.R., et al. Cytotoxic mechanism of XK469: resistance of topoisomerase IIβ knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280 (2001) 1155-1160
7. Mensah-Osman E.J., Al-Katib A.M., Dandashi M.H., and Mohammad R.M. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIβ is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Mol Cancer Ther 1 (2002) 1315-1320
8. Gao H., Yamasaki E.F., Chan K.K., et al. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS. Mol Pharmacol 63 (2003) 1382-1388
9. 2 - M cell cycle arrest by p53-dependent and -independent pathways. Clin Cancer Res 7 (2001) 3336-3342
10. Lin H., Liu X.Y., Subramanian B., Nakeff A., Valeriote F., and Chen B.D. Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. Int J Cancer 97 (2002) 121-128
11. Kessel D., and Horwitz J.P. Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor. Cancer Lett 168 (2001) 141-144
12. Corbett T.H., LoRusso P., Demchick L., et al. Preclinical antitumor efficacy of analogs of XK469 sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs 16 (1998) 129-9
13. Boinpally R.R., Zhou S.L., LoRusso P.M., and Parchment R.E. Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration. Cancer Chemother Pharmacol 55 (2005) 404-407
14. Tosca P.J., Turner N.A., Hassler C.R., et al. Toxicity of R(+)XK469 (NSC-698215) and S(-)XK469 (NSC-698216) in rodents and beagle dogs. Proc Am Assoc Cancer Res 41 (2000) 705 [Abstract 4480]
15. Polin L., White K., Kushner J., et al. Preclinical efficacy evaluations of XK-469 dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs 20 (2002) 13-22
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. Gibaldi M., and Perrier D. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics. 2nd ed. (1982), Marcel-Dekker, New York, NY
18. Alousi A.M., Boinpally R., Wiegand R., et al. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIβ inhibitor. Invest New Drugs 25 (2007) 147-154
19. Undevia S.D., Gomez-Abuin G., and Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5 (2005) 447-458
20. Anderson L.W., Collins J.M., Klecker R.W., et al. Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol 56 (2005) 351-357
21. Kim T.W., Liu W., Undevia S.D., et al. A pharmacogenetic study of aldehyde oxidase in patients treated with R(+)XK69. The Annual Meeting of the Korean Cancer Association (2005), Seoul, Korea
22. Stock W., Undevia S.D., Faderl S., et al. Phase I study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory hematological malignancies. Blood (ASH Annual Abstracts) (2006) 108 [Abstract 1952]